Eilean Therapeutics LLC, a US-based biopharmaceutical company focused on discovering and developing small molecule inhibitors targeting escape mutations in haematologic malignancies and solid tumours, announced on Monday the presentation of data for its brain- and lung-permeable pan-EGFR inhibitor, ZE77-0273, at an upcoming conference hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer.

According to Eilean, ZE77-0273 is a reversible small-molecule drug candidate that demonstrates broad activity against resistance mutations in EGFR-mutant non-small cell lung cancer (NSCLC), a high selectivity index versus wild-type EGFR, and a wide therapeutic window characterised by excellent safety and tolerability.

The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics runs from Wednesday 22 October until Sunday 26 October at the Hynes Convention Centre in Boston, Massachusetts.